期刊
JOURNAL OF CYSTIC FIBROSIS
卷 17, 期 2, 页码 190-203出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jcf.2017.11.003
关键词
Cystic fibrosis; Modifier genes; FAM13A
资金
- French cystic-fibrosis non-profit organization Vaincre la mucoviscidose, a Legs Poix grant
- French cystic-fibrosis non-profit organization Vaincre la mucoviscidose
- French cystic-fibrosis non-profit organizations Vaincre la mucoviscidose
- Agir et Informer Contre la Mucoviscidose (AICM)
- Cystic Fibrosis Foundation [CORVOL16G0]
Background: Cystic fibrosis (CF) lung disease severity is highly variable and dependent on several factors including genetic modifiers. Family with sequence similarity 13 member A (FAM13A) has been previously associated with lung function in the general population as well as in several chronic lung diseases, such as chronic obstructive pulmonary disease (COPD), we examined whether FAA/113A is a modifier gene of CF lung phenotype. We also studied how FAM13A may contribute to the physiopathological mechanisms associated with CF. Methods: We investigated the association of FAMJ3A with lung function in CF French patients (n = 1222) by SNP-wise analysis and Versatile Gene Based Association Study. We also analyzed the consequences of FAM13A knockdown in A549 cells and primary bronchial epithelial cells from CF patients. Results: We found that FAM13A is associated with lung function in CF patients. Utilizing lung epithelial A549 cells and primary human bronchial epithelial cells from CF patients we observed that IL-1 and TGFP, reduced FAM13A expression. Knockdown of FAM13A was associated with increased RhoA activity, induction of F-actin stress fibers and regulation of epithelial-mesenchymal transition markers such as E-cadherin, a-smooth muscle actin and vimentin. Conclusion: Our data show that FAM13A is a modifier gene of CF lung phenotype regulating RhoA activity, actin cytoskeleton dynamics and epithelial-mesenchymal transition. (C) 2017 The Author(s). Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据